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Abstract: The human carboxylesterase 1 (CES1), responsible for the biotransformation of many diverse
therapeutic agents, may contribute to the occurrence of adverse drug reactions and therapeutic
failure through drug interactions. The present study is designed to address the issue of potential
drug interactions resulting from the inhibition of CES1. Based on an ensemble of 10 crystal structures
complexed with different ligands and a set of 294 known CES1 ligands, we used docking (Autodock Vina)
and machine learning methodologies (LDA, QDA and multilayer perceptron), considering the different
energy terms from the scoring function to assess the best combination to enable the identification of
CES1 inhibitors. The protocol was then applied on a library of 1114 FDA-approved drugs and eight
drugs were selected for in vitro CES1 inhibition. An inhibition effect was observed for diltiazem
(IC50 = 13.9 µM). Three others drugs (benztropine, iloprost and treprostinil), exhibited a weak CES1
inhibitory effects with IC50 values of 298.2 µM, 366.8 µM and 391.6 µM respectively. In conclusion,
the binding site of CES1 is relatively flexible and can adapt its conformation to different types of ligands.
Combining ensemble docking and machine learning approaches improves the prediction of CES1
inhibitors compared to a docking study using only one crystal structure.
Keywords: carboxylesterase 1; docking; ensemble docking; machine learning; CES1 inhibitors;
adverse drug reactions; metabolism
1. Introduction
The incidence of drug failures remains high in late-stage clinical development phases, leading to
a key challenge in drug discovery [1]. Essentially this reflects a lack of efficacy and clinical safety [2].
Although drug response is a complex phenotype depending on numerous genetic environmental
and behavioral factors, studies have demonstrated that pharmacokinetics, and notably metabolism,
can alter the response to medicine and lead to increased risk of adverse drug reactions (ADRs) through
for example unanticipated drug–drug interactions (DDIs) [3]. Studies assessing the potential DDIs have
been dedicated mostly to redox enzymes such as cytochromes P450, however, less has been done to
rationalize hydrolytic drug metabolizing enzymes such as human carboxylesterase 1 (CES1) [4].
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CES1 is an enzyme member of the serine hydrolase family. Among the five human
carboxylesterases (CESs), CES1 is the predominant form expressed in the liver [5,6]. CES1 is implicated
in the hydrolysis of many drugs (and prodrugs), transforming an ester, amide or carbamate moiety into
its respective free acids, amines or alcohols [7]. It metabolizes structurally diverse compounds such
as the psychostimulant methylphenidate (MPH) [8] used in the treatment of hyperkinetic disorders,
commonly prescribed angiotensin-converting enzyme (ACE) inhibitors (enalapril, trandolapril,
ramipril, quinapril, imidapril) [9], the anti-cancer agent (CPT-11) [10,11], the anti-influenza prodrug
oseltamivir [12], and several narcotics and analgesics (cocaine, meperidine) [13,14]. CES1-mediated
metabolism can yield either inactive metabolites, as in the deactivation of MPH into ritalinic acid,
or active metabolites, as in the case of prodrugs activation, such as activation of oseltamivir phosphate
to its active form, oseltamivir carboxylate. In addition to xenobiotic substrates, CES1 is also involved in
the processing of several endogenous compounds such as fatty acids and cholesterol derivatives [15,16].
The publication of crystal structures of CES1 has greatly contributed to the understanding of
the mechanism of action of the enzyme. Fourteen X-ray structures of CES1 released in the Research
Collaborator for Structural Bioinformatics (RCSB) Protein Databank were all complexed with a ligand
(substrate analogs, inhibitors, endogenous metabolites, and enzymatic products) [17–20]. In addition,
four new X-ray structures in the apo state have been resolved recently [21,22]. Tremendous efforts
have been devoted by examining both structural and biochemical requirements of these enzymes
to hydrolyze their substrates [23–25], and several early studies reported different types of CESs
inhibitors [26–33].
In-silico studies involving ligand-based approaches have been applied in order to identify
therapeutic agents acting as strong CES1 inhibitors leading to potential drug–drug interactions
(DDIs) [34]. Pharmacophore and QSAR methods have been applied on protease inhibitor antiviral
drugs [35]. 3D-QSAR studies have been performed on a class of compounds based on benzil
(1,2-diphenylethane-1,2-dione) and isatins (Indole-2,3-diones) [28,32]. Structure-based approaches
such as docking and molecular dynamics simulation were also performed to elucidate the mechanisms of
binding, which is essentially the key role of hydrophobic interactions in ligand binding and the flexibility
of the active site to adapt to specific ligands. [29,36,37]. Finally, our previous docking studies
analyzed the underlying mechanism of drug response variability resulting from CES1 polymorphism.
It confirmed the critical role of the Gly143 allele in the metabolism of MPH [38,39] and suggested that
the polymorphism Glu220Gly could also affect the enzyme function [40].
Overall, despite the number of clinical drugs identified as CES1 inhibitors, CES1 inhibition is still
an overlooked source of DDIs. All drugs have not been systematically assessed for their inhibitory
capacity on CES1. Therefore, our study is designed as an attempt to identify clinically prescribed
drugs exhibiting CES1 inhibitory activity with potential for producing CES1-based drug interactions,
using an approach that combines ensemble docking and machine learning methods. Previous studies
have reported that ensemble docking based on molecular dynamics simulations or on multiple
crystallographic structures were more successful than docking based on single conformation [41].
Furthermore, combined with a machine learning approach, it has the advantage of increasing virtual
screening performance while reducing the amount of errors that would be introduced by a single
method [42–44].
2. Results
2.1. Binding Site Description
CES1 exists in a trimer–hexamer equilibrium. Each monomer of the enzyme is composed of three
functional domains namely a central catalytic domain, which contains the serine hydrolase catalytic triad
(Ser221, His468 and Glu354), an α/β domain that stabilizes the trimeric architecture, and a regulatory
domain. The active site is located at the base of a 10–15 Å deep catalytic gorge located at the interface of
the three domains and is predominantly lined by hydrophobic residues. Two acidic negatively-charged
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residues are present in the CES1 cavity, namely, Glu220, Asp90. The catalytic cavity of CES1 is
composed of two substrate-binding pockets: a small and rigid compartment (Leu96, Leu97, Leu100,
Phe101, Leu358) which enables compound selectivity, and a large and flexible pocket (Thr252, Leu255,
Leu304, Leu318, Leu363, Met364, Leu388, Met425, Phe426), which is promiscuous. This composition
confers the ability to act on structurally diverse compounds. Figure 1 presents the human CES1 trimer,
the active site composition and the binding modes of CES1 with the co-crystallized ligand naloxone
(PDB ID 1MX9).
The catalytic triad residues, located between the two pockets, are aligned in a way that favors
the generation of the Ser221 oxygen nucleophile. This nucleophile then attacks the carbonyl carbon of
the ester substrate, leading to the formation of the acyl-enzyme intermediate, which is stabilized by
the oxyanion hole residues Gly142 and Gly143. Additionally, the enzyme has two other ligand-binding
sites referred to as the side-door and the Z-site: The side-door serves as an alternative/additional
opening to the active site for substrate entrance or as a product release pore: The Z-site probably has
an allosteric function by modulation of the binding site accessibility [45,46]. However, the side-door
and the Z-site binding sites were not investigated in this study.
In the case of CES1, we have the luxury of 10 high-quality crystallographic structures
representing a spectrum of pocket conformation, intuitively calling for an ensemble docking
approach. Comparing the volume of the active site of the 10 X-ray structures, we noticed some
differences going from 701 Å3 for 1YAH [19] to 1375 Å3 for 1MX9 [18], almost doubling the size
(Figure S1 in Supplementary Materials). The solvent-accessible surface area (SASA) follows a similar
trend with a SASA value two times higher for 1MX9 (356 Å2) than 1YAH (185 Å2) (Figure S2
in Supplementary Materials). This result shows large flexibility of the enzyme to adapt the accessibility of
its binding site to large and diverse ligands and thus accurately represent different states of CES1 useful
for applying ensemble docking. Therefore, we decided to assess the enrichment of an ensemble docking
approach coupled with machine learning approaches to predict CES1 ligands.
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2.1.1. Evaluation and Validation of Docking Protocol
Redocking was conducted to assess the docking protocol for the given application:
The co-crystallized ligands of eight of the 10 crystal structures were docked back in the defined
binding pocket; and the conformation, orientation and position of the docked poses were compared to
the experimentally determined ones. The two remaining structures (1YA8 and 2DQY) were crystallized
with cleavage products located outside of the active site and could not be meaningfully redocked.
For ligands, homatropine, naloxone, ethyl acetate, benzyl, and palmitate, respectively, a root mean
square deviation (RMSD) between 1.5 Å and 4.7 Å was observed with general conformations visually
similar to their crystallized forms. Three notable outliers were the non-competitive inhibitor tamoxifen
(RMSD around 8 Å) and the two ligands with many flexible bonds, taurocholate (RMSD around 6.7 Å)
and coenzyme A (RMSD around 9 Å) (Figure S1 in Supplementary Materials). The relatively high
RMSD can be explained by the dominance of non-specific hydrophobic interactions in ligand binding,
with a very high average B-factor for the ligands themselves compared to the protein, indicating
mobile ligands in the active site. A recent study has reported that at a resolution around 3 Angstrom,
B-factors around 80 A2 or higher indicate very low quality of the positional information for these atoms
and that could explain our RMSD [47]. Furthermore, despite the high uncertainty over ligand position,
the deposited PDB files do not contain alternate locations, an unfortunate choice that likely does not
reflect the actual ligand-binding behaviour. Including alternate locations for the ligand would have
likely reduced the average B-factor for each individual location [48].
While Autodock Vina may not be suitable for crystallographic pose prediction in this system,
we considered the performance of Autodock Vina adequate for our purpose of screening inhibitors.
2.1.2. Analysis of the Docking Protocol with Known CES1 Ligands
Once the docking tool was validated, exhaustive docking for a set of 294 compounds with a known
inhibition constant (Ki) at CES1 was completed with the 10 X-ray structures. To analyze the performance
of the docking tool, the ROC curve (Receiver Operating Characteristic (ROC) was used, considering
the Vina docking score and a 10 µM Ki threshold, splitting the dataset into an active and inactive
group, with 140 and 154 ligands respectively. An ensemble docking approach was also considered,
by taking the average of the scores of the 10 protein structures (Figure 2). The ROC curves were similar
for seven conformations of the enzyme, showing a general discrimination ability of relatively weak
size (AUC around 0.57–0.62). Two conformations remained close to the center line, with AUC 0.51
and 0.52, meaning that inactive compounds were docked in CES1 with a Vina docking score as good
as for the active compounds. One structure (1YAH) showed inverse discriminative power (AUC 0.38),
corresponding to the worst docking scores for the more active compounds. The ensemble docking (red
line in Figure 2) does not show a better performance (AUC of 0.57) in comparison to many individual
structures. Simple averaging of the score across all structure does not yield better performance. Seeking
to explain such behavior, we noticed that 1YAH binds to the smallest substrate by far (ethyl acetate),
with a corresponding small active site volume and exposed surface area. Small molecules like ethyl
acetate were not found among the known high potency CES1 ligands in our dataset, thus high-scoring
compounds on this protein structure were unlikely to be legitimate hits. Indeed, removing these
false positives increased the discrimination ability of the other structures (elimination of the top 100
scoring compounds on the 1YAH structure allowed the AUC to go up by around 0.05 points for all
other structures).
Interestingly, the ROC curves for most of the structures depict relatively good progress of the True
Positive Rate (TPR) compared to the False Positive Rate (FPR) for the first 20% of the data set.
Beyond the second decile, this metric does not allow prediction much better than chance. Exploring
this finding further, we observed a markedly lower logP in best-scoring compounds (1st decile mean
logP, 1.8; 10th decile, 4.6), as well as a lower molecular weight (mean 163 g/mol to 444 g/mol).
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Figure 2. ROC curves showing the performance of docking based on the average energy score for each
CES1 ligand docked in the 10 CES1 conformations. Each line corresponds to the results of the correct
ranking of active ligands (with an activity below 10 µM) on one X-ray structure of CES1. The red line
(Ensemble) considers the average energy score attributed to a ligand across every X-ray structure used
in the docking protocol. The dashed line represents a random ranking.
To better understand the degree of (dis)agreement on ranking across structure, we computed
a Spearman R rank correlation between the list of the 100 top scoring ligands, for each pair of CES1
structures (Figure 3).
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in the 0.55–0.84 range. Two structures seem isolated from the rest, 1YAH and 2DR0, which depicted
the worst and the best ROC curves with the Vina score. Additionally, there is local disagreement on
compounds ranked (e.g., 1YAJ and 2DQY, 2DR0, and 2H7C), suggesting specific a binding mode of
CES1. Each CES1 structure has between 12 and 51 active ligands in its top 100, three being common in
any of the 10 structures (ChEMBL189162, ChEMBL242722, ChEMBL242932). It means that while there
is significant pairwise overlap, a 10-structure ensemble is not equivalent to any one individual structure
and is able to capture a more diverse set of ligands. When examining the top 100 worst scores of each
structure, we find 35 to 46 active molecules, 33 of which are common to every structure (Table S1).
These 33 ligands do not seem to be highly different to the remaining active ligands. The mean values
for logP and molecular weight are also in the same range as the correctly predicted active compounds.
The existence of a group of active yet badly scoring molecules, without obvious differences in chemical
properties, suggests that docking score alone might not be sufficient to fully characterize ligand activity
on CES1.
2.2. Expert System Based on Energy Terms
Machine learning models using binding energy terms have shown to be an interesting alternative
and complementary approach to predict the activity of ligands to a protein [49]. In Autodock
Vina, selecting the “-score-only” option, we collected six individual terms calculated in the scoring
function i.e., gauss1, gauss2, repulsion, hydrophobic, hydrogen interactions, and the Vina score
(more information about these terms can be found in Ref. [50]). The values of each term for all
the dockings were computed and averaged for each ligand and CES1 structure. In addition to
structure-individualized input data, we evaluated an ensemble approach by taking the average of
each component of the input vector for a given ligand across the 10 structures and resulting poses.
The input data is available in Table S1. Then, three machine learning approaches (LDA, QDA and MLP)
were developed using an arbitrary threshold of 1 µM, 10 µM and 100 µM to separate between active
and inactive CES1 ligands. The performances of the models on a training set, cross validation and test
sets are described in Table 1 and Figure 4. In general, all the models show a better AUC than
the docking score only (between 10% and 20% higher). The AUC remains relatively high on the test
set, demonstrating the robustness of the models. The best model was the neural network (MLP),
followed by the QDA and LDA with a quite similar performance profile. In addition to cross-validation,
to check for overfitting, the possibility of an outsized effect of liminal ligands was investigated by
computing the performances of the classifiers while removing compounds with Ki within 5 µM of
the 10 µM threshold from the dataset (i.e., removing compounds between 5 µM and 15 µM). For both
procedures, there were minimal changes in the evaluation metrics (Figure S3), confirming a limited
bias of compounds around the threshold in the models developed.
It confirms the benefit of combining machine learning approaches with ensemble models to
improve the detection of CES1 ligands. Finally, we developed a MLP classification model using
the entire set of 294 CES1 ligands and a threshold of 10 µM in order to investigate the CES activity of
drugs. With a Matthews coefficient correlation of 0.74, the model shows a good performance and looks
reliable for prediction.
Molecules 2019, 24, 2747 7 of 17
Molecules 2019, 24, x FOR PEER REVIEW 6 of 17 
 
2DR0, which depicted the worst and the best ROC curves with the Vina score. Additionally, there is 
local disagreement on compounds ranked (e.g., 1YAJ and 2DQY, 2DR0, and 2H7C), suggesting 
specific a binding mode of CES1. Each CES1 structure has between 12 and 51 active ligands in its top 
100, three being common in any of the 10 structures (ChEMBL189162, ChEMBL242722, 
ChEMBL242932). It means that while there is significant pairwise overlap, a 10-structure ensemble is 
not equivalent to any one individual structure and is able to capture a more diverse set of ligands. 
When examining the top 100 worst scores of each structure, we find 35 to 46 active molecules, 33 of 
which are common to every structure (Table S1). These 33 ligands do not seem to be highly different 
to the remaining active ligands. The mean values for logP and molecular weight are also in the same 
range as the correctly predicted active compounds. The existence of a group of active yet badly 
scoring molecules, without obvious differences in chemical properties, suggests that docking score 
alone might not be sufficient to fully characterize ligand activity on CES1. 
2.2. Expert System Based on Energy Terms 
Machine learning models using binding energy terms have shown to be an interesting 
alternative and complementary approach to predict the activity of ligands to a protein [49]. In 
Autodock Vina, selecting the “-score-only” option, we collected six individual terms calculated in the 
scoring function i.e., gauss1, gauss2, repulsion, hydrophobic, hydrogen interactions, and the Vina 
score (more information about these terms can be found in Ref. [50]). The values of each term for all 
the dockings were computed and averaged for each ligand and CES1 structure. In addition to 
structure-individualized input data, we evaluated an ensemble approach by taking the average of 
each component of the input vector for a given ligand across the 10 structures and resulting poses. 
The input data is available in Table S1. Then, three machine learning approaches (LDA, QDA and 
MLP) were developed using an arbitrary threshold of 1 µM, 10 µM and 100 µM to separate between 
active and inactive CES1 ligands. The performances of the models on a training set, cross validation 
and test sets are described in Table 1 and Figure 4. In general, all the models show a better AUC than 
the docking score only (between 10% and 20% higher). The AUC remains relatively high on the test 
set, demonstrating the robustness of the models. The best model was the neural network (MLP), 
followed by the QDA and LDA with a quite similar performance profile. In addition to cross-
validation, to check for overfitting, the possibility of an outsized effect of liminal ligands was 
investigated by computing the performances of the classifiers while removing compounds with Ki 
within 5 µM of the 10 µM threshold from the dataset (i.e., removing compounds between 5 µM and 
15 µM). For both procedures, there were minimal changes in the evaluation metrics (Figure S3), 
confirming a limited bias of compounds around the threshold in the models developed. 
 
Figure 4. ROC curves showing the performance of the MLP classifier at a Ki threshold 10 µM, as 
measured on the test set. 
Figure 4. ROC curves showing the pe formance of the MLP classifier at a Ki threshold 10 µM,
as measured on the tes set.
Table 1. Performance of the ensemble models (including the non-machine-learning score-only classifier)
under different activity thresholds and machine learning approaches.
Threshold 1 µM 10 µM 100 µM
Number of active ligands
of the 230 in the training set 76 (33%) 107 (46%) 127 (55%)
of the 64 in the test set 19 (30%) 33 (52%) 36 (56%)
Vina score (no statistical model)
Ensemble AUC (training set) 0.54 0.57 0.63
Best AUC among all individual structures 0.58 0.62 0.66
Ensemble MLP model
AUC (std. dev.) 5CV (training set) 0.84 (0.05) 0.81 (0.03) 0.75 (0.06)
AUC (test set) 0.82 0.90 0.92
Matthews coeff. (test set) 0.49 0.56 0.59
Ensemble LDA model
AUC (std. dev.) 5CV (training set) 0.78 (0.10) 0.77 (0.08) 0.81 (0.07)
AUC (test set) 0.77 0.77 0.77
Matthews coeff. (test set) 0.38 0.34 0.43
Ensemble QDA model
AUC (std. dev.) 5CV (training set) 0.79 (0.12) 0.77 (0.08) 0.81 (0.10)
AUC (test set) 0.76 0.78 0.75
Matthews coeff. (test set) 0.31 0.47 0.39
2.3. Test and Validation of the Protocol to Predict CES1 Inhibitors
Based on the ensemble docking protocol, 1114 FDA-approved drugs were docked on the 10 X-ray
CES1 structures, and the six terms of the scoring function were gathered. Then, using the ensemble
model MLP trained previously on the full set of CES1 ligand, 679 FDA-approved drugs were predicted
to be active on CES1 (Table S2). One of the most represented chemical classes was morphinan.
In addition to the known ligand naloxone, a number of related drugs were rated likely CES1 inhibitors
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by our models (levallorphan, dextromethorphan, naltrexone, methadone, and meperidine among
others). The tetracyclic and tricyclic antidepressants constitute a second family of top-rated potential
CES1 inhibitors (maprotiline, nortriptyline, doxepin, maprotiline, mianserin among others). A few
SSRIs/SNRIs were also found (atomoxetine, sertraline, fluvoxamine, duloxetine). Antidepressants
with a documented inhibitory effect on CES1 include fluoxetine, thioridazine, and perphenazine [35].
Interestingly, the model predicted some steroids to be inhibitors of CES1, such as estriol, estradiol,
testolactone, and testosterone. A handful of anti-muscarinic molecules were also found (procyclidine,
tolterodine). The remaining hits were spread among a variety of pharmacological and chemical
classes like benzodiazepine (zoldipem, clotiazepam, fludiazepam), antihistaminique (promethazine,
trimeprazine), and local anesthetics (lidocaine, procaine, chloroprocaine, bupivacaine). Some of them
were previously demonstrated to inhibit CES1, like diazepam [51].
To validate our model, we tested a set of eight molecules in an in-vitro assay including
benztropine, naloxone, almivopan, iloprost, treprostinil, mepenzolate, trospium, and diltiazem
(Figure 5). The selection of these was made upon consideration of different criteria, namely, the drug
must be predicted as active as well as available and with different pharmacological action (Table 2).
Nalbuphine was also selected, but since it lacked the required solubility in aqueous buffer at pH 7,
we could not perform an experiment on this drug.
The positive control diltiazem displayed an IC50 of 13.9 µM in our assay. The known inhibitor
naloxone was the less potent (617.8 µM). Almivopan exhibited no inhibition even at the highest
concentration. Mepenzolate and trospium did not reach 50% inhibition in our assay (at max
concentration 600 µM, they afforded ~15% and 30% inhibition, respectively). Benztropine was
the second most potent inhibitor of the predicted compounds with an IC50 value of 298.2 µM,
followed by iloprost, which exhibited an IC50 of 366.8 µM and treprostinil with an IC50 of 391.6 µM.
Benztropine has previously been tested on CES1, but no IC50 value was indicated in the study [35].
We can show here that benztropine is a weak inhibitor.
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Table 2. Name, 2D structure, IC50, and pharmacological action of the eight drugs tested in vitro on
a CES1 assay. NS means Non-significant.
Name 2D Structure IC50 (µM) Pharmacological Action
Diltiazem
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3. Discussion
Drug interactions are recognized as a significant factor contributing to the occurrence of
ADRs and their number increases as more drugs are released into the market. There are
different mechanisms by which drug interactions can occur, for instance, in pharmacokinetics-related
mechanisms where drug absorption, distribution, metabolism and/or excretion are affected;
or pharmacodynamics-related mechanisms, when drugs with similar pharmacological actions are
co-prescribed. Knowing the mechanisms involved in drug interactions is essential to be able to predict
and prevent them. CES1 is the major hydrolytic enzyme responsible for the biotransformation of
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many and diverse therapeutic agents including Angiotensin-converting-enzyme inhibitors, anti-cancer
prodrugs, narcotic drugs, methylphenidate, and others. Significant interindividual variability of
pharmacokinetic and pharmacodynamic profiles of these medications, often associated with unforeseen
ADRs and therapeutic failure, has been frequently observed in clinical practice. The main underlying
causes are genetic variation and DDIs [38]. Previously published studies [35,52] have identified some
classes of routinely prescribed medications as potential inhibitors of CES1, however, none of these
studies performed a systematic screening of all clinically-used drugs. Hence, in the present study,
we sought to focus on potential DDI resulting from CES1-mediated metabolism inhibition by clinically
used drugs, using a methodology combining ensemble docking and machine learning approaches.
This protocol allows for an evaluation of large databases of compounds from which only a limited
number of compounds can be selected and experimentally evaluated.
Thanks to the availability of many crystal structures of CES1–ligand complexes,
docking simulations were carried out to unravel molecular-level mechanisms of drug binding potentially
producing inhibitory effects of CES1. Furthermore, using the energies terms calculated in the Vina
score, MLP, LDA and QDA models were performed, improving the prediction of new CES1 ligands.
Using our method on DrugBank, we identified a range of different therapeutic agents
as potential CES1 inhibitors including several commonly used agents such as estrogens and fluoxetine.
Importantly, several of the drugs, which we found to be potential inhibitors of CES1 by our in-silico
approach, have previously been shown to inhibit CES1 in vitro. This includes maprotiline, nortriptyline,
amitriptyline, fluoxetine, sertraline, and estriol. In particular, the SSRI sertraline has been found
to have a strong in-vitro inhibitory effect on the activity of CES1 [35,53]. Overall, our prediction
that many diverse steroids have an inhibitory effect on CES1 is in line with published in-vitro
findings, which have suggested that progesterone, the progesterone metabolite 5β-pregnan-3,20-dione,
testosterone, corticosterone, and deoxycorticosterone, in addition to estrogens, inhibit CES1 [53].
These results demonstrate the usefulness of such approach in validating known biologically active
drugs, but also in identifying new drugs which potentially affect the enzyme. However, the many
and structurally diverse compounds recognized by CES1 lead to the likelihood of numerous binding
modes of inhibitors and substrates and so it can affect the scoring docking poses. Applying a machine
learning approach using the different energies terms from Vina has the advantage to fit the mathematical
model to the previous knowledge data considered (training set) and so to make a decision for
the new compounds investigated. There are other pitfalls, which make the prediction of binding
conformations difficult like the low resolution of crystal structures and more especially conformational
changes that occur upon binding. Receptor flexibility remains a challenge in docking simulations.
Various approaches such as soft-docking strategies, protein side-chain rotamer libraries, ensemble-based
docking, molecular dynamics, and Monte Carlo simulations are able to incorporate some degree of
receptor flexibility into the docking process [54]. Furthermore, the presence of the so called ‘activity
cliffs’, i.e., pairs of structurally similar compounds having a significantly different biological activity can
negatively impact the performance of the similarity searching. Finally, in-vitro testing of the predicted
hits can also be problematic, mainly due to poor water solubility of compounds. All these limitations
have to be considered when such a computational study is developed.
4. Materials and Methods
4.1. Collection and Curation of the Chemical Library
One thousand one hundred and fourteen FDA-approved, non-nutraceutical drugs were collected
from Drugbank 4.0 [55] and a reference dataset of 294 ligands with biological activity on CES1
(documented Ki) was gathered from Chembl [56]. Conformers for those molecules were either retrieved
through PubChem [57], returning the experimental structure conformer if available, or generated using
the open source cheminformatics library, RDKit [58].
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Ligands were converted to PDBQT format using Autodock Tools (Scripps Research Institute),
assigning Gasteiger charges to the atoms at the same time [59]. pH-appropriate protonation was
conducted using OpenBabel (pH set at 7.4) [60]. The molecules were then randomly assigned to
a training set of 230 compounds (80%) and a test set of 64 compounds (20%) for use in the development
and validation of the predictive models. All Tanimoto similarity distances were computed based on
Daylight fingerprint, as implemented in RDKit.
4.2. Protein Preparation and Docking Protocol
The coordinates of the 10 CES1 complexed with different non-covalent ligands were obtained
from the RCSB PDB [61]. The pdb files used in this study are 1MX9, 1YAH, 1MX5, 1YAJ, 1YA4, 2H7C,
1YA8, 2DR0, 2DQZ, and 2DQY. For each structure, using UCSF Chimera [62], only the A chain was
kept, from which water and molecules other than amino acid residues were removed. The Dock
Prep utility was used on the protein for protonation (residue-name based for HIS, GLU, ASP, LYS,
and CYS), assigning charges (using AMBER ff14SB for standard residue, Gasteiger charges otherwise).
The structures were aligned and the amino acid renumbered to ensure direct comparability of docking
results. Active site pocket metrics were assessed using fpocket 3.0 [63], with default parameters except
for a clustering distance of 2.8 angstrom to obtain a single cluster encompassing the active site in
all 10 structures. This setting slightly overestimates pocket volume in absolute value but allows for
a reliable comparison between the structures
4.3. Docking Protocol
Docking was performed using Autodock Vina [59]. A single docking box centered around
the mechanistically-relevant Ser 221 was used, with a size 26 × 28 × 32 Angstrom for the 10 receptor
structures. The exhaustiveness parameter, which corresponds to the amount of sampling effort, was set
to eight, and the desired number of poses to three. Docking scores distribution was examined for
irregularities or outliers. The distance from the ligand centroid to the catalytically important Ser 221
was taken as evidence of the ligand being docked into the active site. For Vina, a large majority of
poses were less than 10 Å from this serine, with a set of outliers at 55 Å.
4.4. Machine Learning Models
Using the python library SciKit-Learn and Keras [64] (using TensorFlow as backend), three types
of machine learning models i.e., Linear Discriminant Analysis (LDA), Quadratic Linear Discriminant
analysis (QDA) and a MultiLayer Perceptron (MLP) were trained to classify active and inactive ligands
using the ChEMBL data. Three thresholds (1 µM, 10 µM, and 100 µM) were used to discriminate
between the two classes (active and inactive ligands). The input data on the models consisted
of the score and five docking terms from the Vina’s score_only mode (gauss1, gauss2, repulsion,
hydrophobic, and hydrogen interactions), all extracted from each pose of the ChEMBL data. One aspect
of the score, namely the entropic term related to the number of rotatable bonds, was not extractable
using score_only mode. However, it is represented in the Vina score itself. The input data were
normalized to mean 0 and variance 1 as a preprocessing step. The necessary scaling was determined
on the training data and used for both training and test data
The multilayer perceptron (MLP) was set up as follows: One input layer of six nodes, two hidden
layers of 16 nodes with sigmoid activation function, and one output layer of one node using the sigmoid
activation function. Batch renormalization was done between the two hidden layers and before
the output layer. The optimizer used was RMSProp, the loss function was binary cross-entropy,
and the batch size was 64. Training was run for 2000 epochs.
Two kind of models were trained. In the 10 structure-individualized models, the input data
generated by docking on a given structure was used. The values of the six components for a given
ligand were obtained by averaging over the three generated poses. On the other hand, in the ensemble
model, the data generated by every structure were considered (using the average overall generated
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poses). The models were trained on a training set of 230 ligands (80%) and validated on a test set
of 64 ligands (20%), which were randomly selected. A five-fold cross validation was performed
on the training set. The performance and robustness of the models were assessed using the AUC,
and Matthews coefficient correlation on the test set.
4.5. In Vitro Assessment of CES1 Inhibition
Benztropine mesylate, mepenzolate bromide, and trospium chloride were ordered
at Sigma-Aldrich (St. Louis, MO, US). Alvimopan was from Toronto Research Chemicals (Toronto,
ON, Canada). Iloprost and treprostinil were from Cayman Chemical (Ann Arbor, MI, US). Diltiazem
hydrochloride was from Napp Pharmaceuticals Research (Cambridge, UK). Naloxone was from LGC
Standards (Middlesex, UK). Recombinant human CES1 was from BD Gentest (Woburn, MA, US).
Inhibition of CES1 by these compounds was investigated by incubation with the recombinant enzyme
in the presence of the ester substrate p-nitrophenyl acetate. The concentration of hydrolytic product,
p-nitrophenol, was determined by measurement of absorbance at 405 nm after 3 min with a Sunrise
microplate reader (Tecan, Grödig, Austria). The incubations were performed in 96-well pureGrade
BRANDplates (BRAND, Wertheim, Germany) in 100 mM phosphate buffer at 37 ◦C in a final volume
of 200 mL. Dimethyl sulfoxide (DMSO) was used for the dissolution of all compounds. The final
concentration of DMSO was 2% v/v in all incubations including the controls. This concentration was
previously found to have a negligible effect on enzyme activity [51]. The substrate and inhibitor
were premixed to allow the simultaneous addition of both. The final concentration of substrate was
100 µM, and the final protein concentration was 10 µg/mL. The potential inhibitors were incubated
at six concentration levels in the range 1–1200 µM. The sampling time was tested to be in the linear
range of the reaction, and the drugs were tested in triplicates. Substrate in buffer without enzyme was
included as a negative control. The results were corrected for spontaneous hydrolysis by subtracting
the absorbance of the negative control and comparing with a positive control containing enzyme,
but no inhibitor. IC50 constants were determined for compounds displaying significant inhibition
using non-linear regression in Prism, version 6.07 (GraphPad Software, Inc., San Diego, CA, USA).
5. Conclusions
Overall, we have demonstrated that a methodology combining ensemble docking and machine
learning methods is a valuable tool for the initial identification of potential new CES1 ligands.
After experimental tests, some of our hits were proven to be novel CES1 inhibitors. Although only
modest inhibitors, they might be pharmacokinetically important in scenarios involving drugs with
narrow therapeutic margins. The clinical relevance of these finding should be investigated further.
Beyond CES1, our in-silico techniques may be applicable more generally to virtual screening for
enzymes with broad substrate selectivity.
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